Ataraxis AI, a developer of AI-powered prognostic tools for oncology, has announced a strategic collaboration with MEDSIR, a global leader in oncology research, to integrate artificial intelligence into multiple major international clinical trials. The studies will analyze data from over 1,000 patients, aiming to identify biomarkers that optimize treatment strategies for breast cancer, including CDK4/6 inhibitors and antibody-drug conjugates (ADCs).
MEDSIR has a long history of supporting transformative oncology therapies, helping novel treatments reach clinical practice and improving patient outcomes worldwide. Ataraxis AI addresses the growing challenge of selecting the right therapy for the right patient with its Ataraxis Breast platform, the first AI-native solution designed to predict outcomes and treatment effects in breast cancer. By combining digital pathology slide analysis with clinical data, the platform provides oncologists with evidence-based insights to support personalized treatment decisions.
AI-Driven Decision Support in Oncology
Building on prior clinical validation demonstrating efficacy across major breast cancer subtypes, the collaboration will leverage Ataraxis AI to predict outcomes for HR+ and HER2+ cohorts, covering both early-stage and metastatic disease. The goal is to enhance clinical decision-making by integrating AI-driven predictions directly into oncology workflows.
“Breast cancer treatment continues to improve, but selecting the right drug at the right time remains a challenge,” said Jan Witowski, CEO and Co-Founder of Ataraxis AI. “We are proud to partner with MEDSIR to validate our breast cancer platform using data from practice-changing clinical trials.”
Alicia García, Scientific Director at MEDSIR, added: “Partnering with Ataraxis AI allows us to integrate cutting-edge AI into clinical trials, generating evidence that can transform treatment decision-making. This collaboration represents a step toward making precision oncology a standard of care.”
Expanding Global Clinical Evidence
The collaboration also marks a milestone in the evolution of Ataraxis Breast, moving beyond retrospective studies into prospective trials investigating new therapies. With MEDSIR’s network of over 600 researchers across 200 sites in 14 countries and Ataraxis AI’s partnerships with more than 40 institutions, the collaboration underscores a global commitment to accelerating AI-driven innovation in oncology.
By combining AI prognostics with high-quality clinical trial data, this initiative aims to improve treatment personalization, patient outcomes, and clinical efficiency, reinforcing a future where precision oncology is both actionable and evidence-based.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
